This story was originally published in The Highlight, Vox’s member-exclusive magazine. To get early access to member-exclusive stories every month, join the Vox Membership program today. We are nearing a point of no return for GLP-1 drugs. More than one in 10 Americans have already taken a GLP-1 agonist, be it Ozempic, Wegovy or Mounjaro. The medications, […]